JESSE BACH: Open Payments
NPI 1144849985 · MINNEAPOLIS, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,140 in 191 payments from 15 companies in 2025. Trend: 2023 $22 · 2024 $639 · 2025 $3,140
Food & beverage: $3,140
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 46 | $442 |
| ABBVIE INC. | 25 | $387 |
| QOL Medical, LLC | 11 | $296 |
| Janssen Biotech, Inc. | 16 | $292 |
| Ardelyx, Inc. | 15 | $287 |
| Celltrion USA Inc. | 16 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $248 |
| GENZYME CORPORATION | 7 | $194 |
| PFIZER INC. | 17 | $178 |
| Ipsen Biopharmaceuticals, Inc | 7 | $169 |
Products named: XIFAXAN, Sucraid, TREMFYA, IBSRELA, VEGZELMA, DUPIXENT, VELSIPITY, RINVOQ.
Industry payments across MN — which companies pay providers there.
